Clinical Trials for Hematologic Cancers

45 Open Trials

Trial Type &
Disease
Protocol No. &
Open Date
Summary
Basic Science
Leukemia
VICCHEM1305
04/02/2013
Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)
Basic Science
Lymphoma;
Pediatric Lymphoma
COGAHOD04B1
10/05/2011
AHOD04B1 - Hodgkin Disease (HD) Banking Study
Basic Science
Hematologic
VICCBMT1063
07/27/2011
T-Regulatory Homing Subsets as a Predictor of Response in GVHD Treated with Extracorporeal Photopheresis
Basic Science
Leukemia
COGAALL08B1
10/18/2010
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Basic Science
Hematologic
NMDPBMT0346
07/09/2003
Repository for National Donor Program (NMDP) Research Blood Samples.
Other
Hematologic
VICCBMT1380
02/05/2014
Chronic GVHD Response Measures Validation
Other
Leukemia
VICCPED0995
02/18/2010
Detection of Donor-Derived DNA in Semen Samples Among Recipients of Allogeneic Hematopoietic Stem-Cell Transplants
Other
Hematologic
ECOGHEME3903
06/07/2005
Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders
Other
Hematologic
VICCBMT1110
11/02/2001
Hematopoietic Stem Cell Transplantaion and Marrow Toxic Injuries (Registry)
Supportive Care
Leukemia;
Lymphoma
VICCBMT1335
02/18/2014
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP01113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Supportive Care
Hematologic;
Leukemia;
Multiple Myeloma
VICCBMT12104
02/04/2014
Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)
Supportive Care
Leukemia
PRECOGHEM0901
12/04/2012
Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission
Supportive Care
Leukemia;
Myelodysplastic Syndrome
VICCBMT1218
09/04/2012
A Randomized, Prospective, Double Blind, Placebo-Controlled, Phase 3 Study of US-ATG-F Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients after Allogeneic Stem Cell Transplantation from Unrelated Donors
Supportive Care
Leukemia;
Pediatric Leukemia
COGACCL0933
11/16/2011
A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Treatment
Leukemia
VICCHEM13110
04/11/2014
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Treatment
Lymphoma
VICCHEM13106
04/09/2014
A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least One Prior Multi-Agent Chemotherapy Regimen in Subjects Who Are Not Candidates for ASCT
Treatment
Lymphoma
VICCHEM13105
04/09/2014
A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)
Treatment
Hematologic
VICCHEM1274
03/31/2014
A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Treatment
Hematologic
VICCPED1354
03/17/2014
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients
Treatment
Multiple Myeloma
VICCHEM1377
03/14/2014
A Phase 1 Study of Arry-520 and Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Treatment
Leukemia;
Lymphoma;
Multiple Myeloma
VICCHEM1392
03/12/2014
A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies
Treatment
Hematologic;
Leukemia
VICCHEM1346
01/21/2014
A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
Treatment
Lymphoma
VICCHEM12103
12/31/2013
Multi-center Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-Chop
Treatment
Leukemia
VICCHEM1336
12/09/2013
A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy
Treatment
Leukemia
VICCHEM1323
10/03/2013
A Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib
Treatment
Multiple Myeloma
VICCHEM1319
08/07/2013
A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
Treatment
Leukemia
ECOGHEMS1203
07/26/2013
A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Treatment
Leukemia;
Lymphoma;
Pediatric Leukemia;
Pediatric Lymphoma
VICCPED1338
06/27/2013
T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies
Treatment
Lymphoma
VICCHEM1284
06/05/2013
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Treatment
Multiple Myeloma
VICCHEM12107
03/31/2013
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)
Treatment
Leukemia
VICCHEM1294
02/25/2013
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission
Treatment
Leukemia
VICCHEM1289
01/04/2013
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML
Treatment
Hematologic
VICCHEM1180
01/04/2013
An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50 X10 9/L to 100 X10 9/L
Treatment
Lymphoma
VICCHEM1146
08/14/2012
Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma
Treatment
Leukemia;
Pediatric Leukemia
VICCPED1186
06/11/2012
CA180-372 / AALL1122 - A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib (IND# 66, 971) Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Treatment
Adrenocortical;
Bladder;
Breast;
Cervical;
Colon;
Dermatologic;
Esophageal;
GIST;
Gastric/Gastroesophageal;
Gynecologic;
Head/Neck;
Kidney (Renal Cell);
Liver;
Lung;
Multiple Myeloma;
Neuroendocrine;
Ovarian;
Pancreatic;
Prostate;
Rectal;
Sarcoma;
Small Cell;
Uterine
VICCMD1188
06/08/2012
An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
Treatment
Hematologic
VICCBMT1148
05/11/2012
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation (Consortium)
Treatment
Leukemia;
Pediatric Leukemia
COGAALL1131
04/05/2012
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum
Treatment
Leukemia
ECOGHEME2906
01/20/2012
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)
Treatment
Lymphoma
VICCBMT1129
11/17/2011
A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX for the Treatment of Patients with Moderate to Severe Chronic Graft vs Host Disease
Treatment
Leukemia
VICCHEM1096
10/24/2011
A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Treatment
Hematologic
VICCBMT1158
10/20/2011
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and other Indications
Treatment
Hematologic
VICCBMT1071
08/01/2011
Targeted Therapy for Bronchiolitis Obliterans Syndrome (BOS)
Treatment
Lymphoma
VICCDERM1059
06/01/2011
Phase IV Randomized Study of Two Dose Levels of Targretin Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma
Treatment
Lymphoma
ECOGHEME2408
05/10/2011
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

You do not have JavaScript enabled. This site works better with JavaScript turned on.